Announcement from Shijiazhuang Yiling Pharmaceutical Co., Ltd. Regarding the Obtaining of Drug Registration Certificate for Aniline Profen Injection by its Wholly-Owned Subsidiary

The Company and all members of its Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and that there are no false records, misleading statements, or material omissions.
Recently, Yiling Wanzhou International Pharmaceutical Co., Ltd. (hereinafter referred to as " Yiling Wanzhou " ) , a wholly-owned subsidiary of Shijiazhuang Yiling Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company"), received approval from the National Medical Products Administration (NMPA) for its application for marketing authorization of anilineprofen injection submitted to the Center for Drug Evaluation of the NMPA, and obtained a drug registration certificate.
The relevant information is hereby announced as follows:
I. Basic Information about the Drugs
Certificate Number : 2026S0076
Generic name of the drug: Anilineprofen Injection
Product Name: Wan Shu An
Approval Number: National Drug Approval Number H 20260006
Dosage form: Injection
Specifications: 4ml : 94.25mg
Registration Classification: Chemical Drugs , Class 2.1 and Class 2.2
Application Item: Drug Registration (Domestic Production)
Approval Conclusion: In accordance with the "Drug Administration Law of the People's Republic of China" and relevant regulations, after review, this product meets the relevant requirements for drug registration and is hereby approved for registration, and a drug registration certificate is issued. The quality standards, instructions, labels, and manufacturing processes shall be implemented as attached. Drug manufacturers must comply with the requirements of Good Manufacturing Practices (GMP) before they can produce and sell drugs.
Marketing Authorization Holder: Yiling Wanzhou International Pharmaceutical Co., Ltd.
Manufacturer: Hebei Kaiwei Pharmaceutical Co., Ltd.
II. Other relevant information about the medicine
Anilineprofen injection is the first chemical drug patented and approved for marketing by Yiling Wanzhou. Anilineprofen is an arylalkyl acid nonsteroidal anti-inflammatory drug (NSAID), which decomposes in the body into biphenylacetic acid. The analgesic mechanism of biphenylacetic acid may be related to its inhibition of prostaglandin synthesis. Anilineprofen injection is mainly used for postoperative analgesia after open abdominal surgery, laparoscopic surgery, and thoracoscopic surgery.
According to data from the National Bureau of Statistics, in 2024 , China's medical and health institutions admitted 312 million patients and performed 104 million surgeries , representing an 8% year-on-year increase compared to 2023 .
The "Guidelines for Perioperative Pain Management in Abdominal Surgery ( 2025 Edition) ," jointly released by the Chinese Society of Surgery and the Chinese Society of Anesthesiology , points out that nonsteroidal anti-inflammatory drugs (NSAIDs) are an important component of multimodal perioperative analgesia. The approval of anilineprofen injection provides a new treatment option for postoperative analgesia in clinical practice.
III. Key Risk Warnings
The registration approval for anilineprofen injection signifies that Yiling Wanzhou is qualified to sell this product in the domestic market, enriching the company's chemical drug product pipeline and bringing a positive impact on the company's expansion in the chemical drug market.
The production and sales of pharmaceuticals are easily affected by changes in market policies and competition. Investors are advised to make prudent decisions and be aware of investment risks.
This is to announce.
Shijiazhuang Yiling Pharmaceutical Co., Ltd.
Board of Directors
January 23 , 2026

https://mp.weixin.qq.com/s/g9zbs2TqVTdKCP5_MTin_A